| Literature DB >> 33645304 |
Anna-Katharin Theuser1, Sophia Antoniadis1, Hanna Langemann1, Sonja Wasner1, Katharina Grasruck1, Svenja Dietzel-Drentwett2, Peter A Fasching1, Matthias W Beckmann1, Carolin C Hack1.
Abstract
PURPOSE: Increasing numbers of breast cancer survivors have led to a growing demand for integrative medicine. When patients have completed treatments associated with severe side effects, attention turns to reducing psychological symptoms, coping behavior, and self-care. The aim of this study was to assess patient-reported benefits in relation to active participation, mind-body stabilization, and coping strategies in breast cancer patients receiving integrative medicine.Entities:
Keywords: active participation; breast cancer; complementary and alternative medicine; coping; integrative medicine; mind–body; oncology
Year: 2021 PMID: 33645304 PMCID: PMC7924003 DOI: 10.1177/1534735421990108
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Characteristics of the Patients (n = 75), Showing Absolute Numbers, Percentages, and Means.
| Characteristics | N | % | Mean (SD) |
|---|---|---|---|
| Age at baseline (years) | 52.5 (12.1) | ||
| ≤40 | 13 | 17.3 | |
| 41-60 | 43 | 57.3 | |
| >60 | 19 | 25.3 | |
| Disease state at baseline[ | |||
| Neoadjuvant | 24 | 32.0 | |
| Adjuvant | 36 | 48.0 | |
| Palliative | 15 | 20.0 | |
| Recurrence state at baseline | |||
| Primary breast cancer | 61 | 81.0 | |
| Recurrence | 14 | 19.0 | |
| Cancer treatment at baseline[ | 58 | 77.0 | |
| Chemotherapy | 38 | 50.7 | |
| Endocrine therapy | 18 | 24.0 | |
| Targeted therapy | 13 | 17.3 | |
| Combined therapies | 20 | 27.0 | |
| Cancer treatment at follow-up (after at least 2 mo)[ | 63 | 84.0 | |
| Chemotherapy | 19 | 25.0 | |
| Endocrine therapy | 38 | 51.0 | |
| Targeted therapy | 14 | 19.0 | |
| Combined therapies | 28 | 37.0 | |
| Concomitant diseases | 55 | 73.0 | |
| Experience with integrative medicine | 68 | 91.0 | |
Missing values were not included in the analysis. Multiple responses were permitted for systemic therapies.
Missing values: 1.
Multiple responses allowed.
Achievement of Individual Treatment Goals as Evaluated by Patients at the Follow-Up Interview, Showing the Numbers of Patients with Each Treatment Goal, Percentages, Means, and Medians.[a]
| Treatment goal | Patients with treatment goal at baseline (n = 75) | Patients with treatment goals achieved (Grades 1-2) | Patients with treatment goals partly achieved (Grades 3-4) | Patients with treatment goals not achieved (Grades 5-6) | Don’t know/k.A. (%) | Mean grade | Median grade | Range of grades |
|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |||||
| Reduced side effects of conventional therapy | 60 (80.0) | 26 (43.3) | 20 (33.3) | 2 (3.3) | 12 (20.0) | 2.6 | 2 | 1-6 |
| Improvement of disease-related quality of life | 56 (74.7) | 26 (46.4) | 20 (35.7) | 2 (3.6) | 8 (14.3) | 2.5 | 2 | 1-6 |
| Improvement in coping with cancer | 42 (56.0) | 19 (45.2) | 14 (33.3) | 3 (7.1) | 6 (14.3) | 2.7 | 2 | 1-6 |
| Mind-body stabilization | 59 (78.7) | 24 (40.7) | 29 (49.2) | 3 (5.1) | 3 (5.1) | 2.8 | 3 | 1-6 |
| Active participation in cancer treatment | 56 (74.7) | 41 (73.2) | 10 (17.9) | 1 (1.8) | 4 (7.1) | 2.0 | 2 | 1-6 |
At the follow-up interview, the patients were asked how satisfied they were with the extend to which their treatment goals has been achieved (1, very satisfied, 2 satisfied, 3 partly satisfied, 4 partly dissatisfied, 5 dissatisfied, 6 very dissatisfied; I don’t know). Of the 75 patients enrolled, only the patients who stated each therapy goal at the baseline were included in the analysis of the achievement of individual therapy goals.
Active Participation in Cancer Treatment (n = 56).[*]
| Achieved | Partly achieved | Not achieved |
| |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Age | ||||
| ≤40 | 11 (21) | 2 (4) | 0 (0) | .531[ |
| 41-60 | 29 (56) | 5 (10) | 1 (2) | |
| ≥60 | 1 (2) | 3 (6) | 0 (0) | |
| Concomitant diseases | ||||
| Yes | 27 (52) | 9 (17) | 1 (2) | .372[ |
| No | 14 (27) | 1 (2) | 0 (0) | |
| Experience with integrative medicine or CAM | ||||
| Yes | 37 (71) | 9 (17) | 1 (2) | .742[ |
| No | 4 (8) | 1 (2) | 0 (0) | |
| Treatment state at initial presentation | ||||
| Neoadjuvant | 15 (29) | 5 (10) | 0 (0) | .252[ |
| Adjuvant | 19 (36) | 4 (8) | 1 (2) | |
| Palliative | 7 (13) | 1 (2) | 0 (0) | |
| Treatment state at follow-up | ||||
| Palliative, progressive disease | 0 (0) | 2 (4) | 0 (0) | .018[ |
| Palliative, stable disease | 7 (13) | 0 (0) | 0 (0) | |
| Curative, undergoing therapy | 12 (25) | 1 (2) | 0 (0) | |
| Curative, tumor-free | 22 (42) | 7 (13) | 1 (2) | |
| Current cancer therapy at initial presentation | ||||
| Chemotherapy | ||||
| Yes | 22 (42) | 6 (12) | 1 (2) | .866[ |
| No | 19 (37) | 4 (8) | 0 (0) | |
| Endocrine therapy | ||||
| Yes | 9 (17) | 0 (0) | 0 (0) | .715[ |
| No | 32 (61) | 10 (20) | 1 (2) | |
| Targeted therapy | ||||
| Yes | 5 (10) | 2 (4) | 0 (0) | .829[ |
| No | 36 (69) | 8 (15) | 1 (2) | |
| Combined therapies | ||||
| Yes | 9 (17) | 3 (6) | 0 (0) | .842[ |
| No | 32 (62) | 7 (13) | 1 (2) | |
| Current cancer therapy at follow up | ||||
| Chemotherapy | ||||
| Yes | 8 (15) | 3 (6) | 0 (0) | .530[ |
| No | 33 (63) | 7 (16) | 1 (2) | |
| Endocrine therapy | ||||
| Yes | 23 (44) | 4 (8) | 1 (2) | .867[ |
| No | 18 (35) | 6 (12) | 0 (0) | |
| Targeted therapy | ||||
| Yes | 6 (12) | 1 (2) | 0 (0) | .488[ |
| No | 35 (67) | 9 (17) | 1 (2) | |
| Combined therapies | ||||
| Yes | 13 (25) | 3 (6) | 1 (2) | .147[ |
| No | 28 (54) | 7 (13) | 0 (0) | |
Only patients who stated this goal at baseline were included in the analysis (achieved = rated at 1 + 2; partly achieved = rated at 3 + 4; not achieved = rated at 5 + 6); significance level 0.05; missing values: 4 (no answers on treatment goal).
Spearman’s rank correlation.
Kruskal-Wallis test.
Mind-Body Stabilization (n = 56).[*]
| Achieved | Partly achieved | Not achieved |
| |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Age | ||||
| ≤40 | 3 (5) | 4 (7) | 1 (2) | .357[ |
| 41-60 | 19 (34) | 14 (25) | 2 (4) | |
| ≥60 | 2 (4) | 11 (20) | 0 (0) | |
| Concomitant diseases | ||||
| Yes | 20 (36) | 22 (39) | 2 (4) | .839[ |
| No | 4 (7) | 7 (13) | 1 (2) | |
| Experience with integrative medicine or CAM | ||||
| Yes | 22 (39) | 28 (50) | 3 (5) | .403[ |
| No | 2 (4) | 1 (2) | 0 (0) | |
| Treatment state at initial presentation | ||||
| Neoadjuvant | 8 (14) | 12 (33) | 1 (2) | .791[ |
| Adjuvant | 11 (20) | 11 (20) | 2 (4) | |
| Palliative | 5 (9) | 6 (11) | 0 (0) | |
| Treatment state at follow-up | ||||
| Palliative, progressive disease | 1 (2) | 4 (7) | 1 (2) | .155[ |
| Palliative, stable disease | 4 (7) | 2 (4) | 0 (0) | |
| Curative, undergoing therapy | 4 (7) | 9 (16) | 0 (0) | |
| Curative, tumor-free | 15 (27) | 13 (23) | 2 (4) | |
| Current cancer therapy at initial presentation | ||||
| Chemotherapy | ||||
| Yes | 10 (18) | 19 (34) | 1 (2) | .200[ |
| No | 14 (25) | 10 (18) | 2 (4) | |
| Endocrine therapy | ||||
| Yes | 7 (13) | 2 (4) | 1 (2) | .193[ |
| No | 17 (30)4 | 27 (48) | 2 (4) | |
| Targeted therapy | ||||
| Yes | 5 (9) | 5 (9) | 0 (0) | .891[ |
| No | 19 (34) | 24 (43) | 3 (5) | |
| Combined therapies | ||||
| Yes | 9 (16) | 4 (7) | 1 (2) | .254[ |
| No | 15 (27) | 25 (45) | 2 (4) | |
| Current cancer therapy at follow up | ||||
| Chemotherapy | ||||
| Yes | 4 (7) | 8 (14) | 1 (2) | .133[ |
| No | 20 (36) | 21 (38) | 2 (4) | |
| Endocrine therapy | ||||
| Yes | 11 (20) | 14 (25) | 2 (4) | .759[ |
| No | 13 (23) | 15 (27) | 1 (2) | |
| Targeted therapy | ||||
| Yes | 4 (7) | 6 (11) | 0 (0) | .715[ |
| No | 20 (36) | 23 (41) | 3 (5) | |
| Combined therapies | ||||
| Yes | 7 (13) | 12 (21) | 2 (4) | .116[ |
| No | 17 (30) | 17 (30) | 1 (2) | |
Only patients who stated this goal at baseline were included in the analysis (achieved = rated at 1 + 2; partly achieved = rated at 3 + 4; not achieved = rated at 5 + 6); significance level 0.05; missing values: 3 (no answers on treatment goal).
Spearman’s rank correlation.
Kruskal-Wallis test.
Improvement in Coping with the Disease (n = 36).[*]
| Achieved | Partly achieved | Not achieved |
| |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Age | ||||
| ≤40 | 5 (14) | 2 (6) | 1 (3) | .811[ |
| 41-60 | 13 (36) | 10 (28) | 2 (6) | |
| ≥60 | 1 (3) | 2 (6) | 0 (0) | |
| Concomitant diseases | ||||
| Yes | 15 (42) | 8 (22) | 2 (6) | .214[ |
| No | 4 (11) | 6 (17) | 1 (3) | |
| Experience with integrative medicine or CAM | ||||
| Yes | 17 (47) | 13 (36) | 3 (8) | .621[ |
| No | 2 (6) | 1 (3) | 0 (0) | |
| Treatment state at initial presentation | ||||
| Neoadjuvant | 6 (17) | 7 (47) | 1 (3) | .406[ |
| Adjuvant | 10 (28) | 2 (6) | 2 (6) | |
| Palliative | 3 (8) | 5 (14) | 0 (0) | |
| Treatment state at follow-up | ||||
| Palliative, progressive disease | 1 (3) | 1 (3) | 1 (3) | .684[ |
| Palliative, stable disease | 2 (6) | 3 (8) | 0 (0) | |
| Curative, undergoing therapy | 4 (11) | 5 (14) | 0 (0) | |
| Curative, tumor-free | 12 (33) | 5 (14) | 2 (6) | |
| Current cancer therapy at initial presentation | ||||
| Chemotherapy | ||||
| Yes | 9 (25) | 9 (25) | 2 (6) | .229[ |
| No | 10 (28) | 5 (14) | 1 (3) | |
| Endocrine therapy | ||||
| Yes | 4 (11) | 2 (6) | 1 (3) | .635[ |
| No | 15 (42) | 12 (33) | 2 (6) | |
| Targeted therapy | ||||
| Yes | 3 (8) | 4 (11) | 0 (0) | .590[ |
| No | 16 (44) | 10 (28) | 3 (8) | |
| Combined therapies | ||||
| Yes | 6 | 4 (11) | 1 (3) | .926[ |
| No | 13 | 10 (28) | 2 (6) | |
| Current cancer therapy at follow up | ||||
| Chemotherapy | ||||
| Yes | 4 (11) | 4 (11) | 1 (3) | .554[ |
| No | 15 (42) | 10 (28) | 2 (6) | |
| Endocrine therapy | ||||
| Yes | 7 (19) | 8 (22) | 2 (6) | .252[ |
| No | 12 (33) | 6 (17) | 1 (3) | |
| Targeted therapy | ||||
| Yes | 1 (3) | 3 (8) | 0 (0) | .265[ |
| No | 18 (50) | 11 (31) | 3 (8) | |
| Combined therapies | ||||
| yes | 4 (11) | 6 (17) | 2 (6) | .128[ |
| No | 15 (42) | 8 (22) | 1 (3) | |
Only patients who stated this goal at baseline were included in the analysis (achieved = rated at 1 + 2; partly achieved = rated at 3 + 4; not achieved = rated at 5 + 6); significance level 0.05; missing values: 6 (no answers on treatment goal).
Spearman’s rank correlation.
Kruskal-Wallis test.